Lilly climbs as FDA approves gradual dosing for Alzheimer's drug

Shares of drugmaker Eli Lilly LLY.N rise 1.8% to $791.85

Co says the U.S. FDA approved changing the prescribing information for its Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous type of brain swelling

Says the new dosing recommendation is to start with a single vial, adding a vial each month until reaching the full four-vial dose at month four

The previous schedule was for two vials monthly until moving to the full dose at month four

Including session's move, stock up 2.4% YTD